Literature DB >> 26125460

Long-term Follow-up Study of Fecal Microbiota Transplantation for Severe and/or Complicated Clostridium difficile Infection: A Multicenter Experience.

Olga C Aroniadis1, Lawrence J Brandt, Adam Greenberg, Thomas Borody, Colleen R Kelly, Mark Mellow, Christina Surawicz, Leslie Cagle, Leila Neshatian, Neil Stollman, Andrea Giovanelli, Arnab Ray, Robert Smith.   

Abstract

GOAL: Our aim was to investigate fecal microbiota transplantation (FMT) efficacy in patients with severe and/or complicated Clostridium difficile infection (CDI).
BACKGROUND: FMT is successful for recurrent CDI, although its benefit in severe or complicated CDI has not specifically been evaluated. STUDY
METHODS: A multicenter long-term follow-up study was performed in patients who received FMT for severe and/or complicated CDI (diagnosed using standard criteria). Pre-FMT and post-FMT questionnaires were completed. Study outcomes included cure rates and time to resolution of symptoms.
RESULTS: A total of 17 patients (82% inpatients, 18% outpatients) were included (76.4% women; mean age, 66.4 y; mean follow-up, 11.4 mo). Patients had severe and complicated (76.4%) or either severe or complicated (23.6%) CDI. Sixteen patients (94.1%) had diarrhea, which resolved in 12 (75%; mean time to resolution, 5.7 d) and improved in 4 (25%) after FMT. Eleven patients (64.7%) had abdominal pain, which resolved in 8 (72.7%; mean time to resolution, 9.6 d) and improved in 3 (27.3%) after FMT. Two of 17 patients experienced early CDI recurrence (≤90 d) after FMT (primary cure rate, 88.2%); and in 1 patient, a second FMT resulted in cure (secondary cure rate, 94.1%). Late CDI recurrence (≥90 d) was seen in 1 of 17 patients (5.9%) in association with antibiotics and was successfully treated with a repeat FMT. No adverse effects directly related to FMT occurred.
CONCLUSIONS: FMT was successful and safe in this cohort of patients with severe or complicated CDI. Primary and secondary cure rates were 88.2% and 94.1%, respectively.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26125460     DOI: 10.1097/MCG.0000000000000374

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  35 in total

Review 1.  Gastrointestinal dysbiosis and the use of fecal microbial transplantation in Clostridium difficile infection.

Authors:  L Patrick Schenck; Paul L Beck; Justin A MacDonald
Journal:  World J Gastrointest Pathophysiol       Date:  2015-11-15

Review 2.  Technical Aspects of Fecal Microbial Transplantation (FMT).

Authors:  N Bhutiani; J E Schucht; K R Miller; Stephen A McClave
Journal:  Curr Gastroenterol Rep       Date:  2018-06-09

3.  Fecal Microbiota Transplantation for Clostridioides difficile in High-Risk Older Adults Is Associated with Early Recurrence.

Authors:  Yuying Luo; Emily N Tixier; Ari M Grinspan
Journal:  Dig Dis Sci       Date:  2020-02-20       Impact factor: 3.199

4.  Nonantimicrobial drug targets for Clostridium difficile infections.

Authors:  Charles Darkoh; Magdalena Deaton; Herbert L DuPont
Journal:  Future Microbiol       Date:  2017-07-31       Impact factor: 3.165

Review 5.  The Present Status of Fecal Microbiota Transplantation and Its Value in the Elderly.

Authors:  Yao-Wen Cheng; Monika Fischer
Journal:  Curr Treat Options Gastroenterol       Date:  2017-09

6.  Fecal microbiota transplant in severe and severe-complicated Clostridium difficile: A promising treatment approach.

Authors:  Monika Fischer; Brian Sipe; Yao-Wen Cheng; Emmalee Phelps; Nicholas Rogers; Sashidhar Sagi; Matthew Bohm; Huiping Xu; Zain Kassam
Journal:  Gut Microbes       Date:  2016-12-21

7.  Intestinal microbiota and the efficacy of fecal microbiota transplantation in gastrointestinal disease.

Authors:  Olga C Aroniadis; Lawrence J Brandt
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-04

8.  Durability and Long-term Clinical Outcomes of Fecal Microbiota Transplant Treatment in Patients With Recurrent Clostridium difficile Infection.

Authors:  Yafet Mamo; Michael H Woodworth; Tiffany Wang; Tanvi Dhere; Colleen S Kraft
Journal:  Clin Infect Dis       Date:  2018-05-17       Impact factor: 9.079

Review 9.  Carbapenem-Resistant Enterobacteriaceae in Solid Organ Transplantation: Management Principles.

Authors:  Olivia Smibert; Michael J Satlin; Anoma Nellore; Anton Y Peleg
Journal:  Curr Infect Dis Rep       Date:  2019-06-10       Impact factor: 3.725

Review 10.  The Potential for Emerging Microbiome-Mediated Therapeutics in Asthma.

Authors:  Ayse Bilge Ozturk; Benjamin Arthur Turturice; David L Perkins; Patricia W Finn
Journal:  Curr Allergy Asthma Rep       Date:  2017-08-10       Impact factor: 4.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.